{"id":"https://openalex.org/W4410829664","doi":"https://doi.org/10.1007/s40268-025-00511-y","title":"Network Meta-Analysis of Pharmacological Therapies for Long-Term Prophylactic Treatment of Patients with Hereditary Angioedema","display_name":"Network Meta-Analysis of Pharmacological Therapies for Long-Term Prophylactic Treatment of Patients with Hereditary Angioedema","publication_year":2025,"publication_date":"2025-05-28","ids":{"openalex":"https://openalex.org/W4410829664","doi":"https://doi.org/10.1007/s40268-025-00511-y","pmid":"https://pubmed.ncbi.nlm.nih.gov/40434599","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/12185836"},"language":"en","primary_location":{"id":"doi:10.1007/s40268-025-00511-y","doi":"https://doi.org/10.1007/s40268-025-00511-y","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40268-025-00511-y","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40268-025-00511-y.pdf","source":{"id":"https://openalex.org/S35266406","display_name":"Drugs in R&D","issn_l":"1174-5886","issn":["1174-5886","1179-6901"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","oarl","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs in R&D","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://link.springer.com/content/pdf/10.1007/s40268-025-00511-y.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Sarah Walsh","orcid":"https://orcid.org/0000-0003-2988-6506","observed_orcids":["https://orcid.org/0000-0003-2988-6506"]},"institutions":[{"id":"https://openalex.org/I4210153140","display_name":"EVERSANA (Canada)","ror":"https://ror.org/04vgfdj66","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210153140"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Sarah Walsh","raw_affiliation_strings":["EVERSANA, 113-3228 South Service Road, Burlington, Ontario L7N 3H8, Canada"],"raw_orcid":"https://orcid.org/0000-0003-2988-6506","affiliations":[{"raw_affiliation_string":"EVERSANA, 113-3228 South Service Road, Burlington, Ontario L7N 3H8, Canada","institution_ids":["https://openalex.org/I4210153140"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055997814","display_name":"Meaghan Bartlett","orcid":"https://orcid.org/0000-0003-4616-8776","observed_orcids":["https://orcid.org/0000-0003-4616-8776"]},"institutions":[{"id":"https://openalex.org/I4210153140","display_name":"EVERSANA (Canada)","ror":"https://ror.org/04vgfdj66","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210153140"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Meaghan Bartlett","raw_affiliation_strings":["EVERSANA, 113-3228 South Service Road, Burlington, Ontario L7N 3H8, Canada"],"raw_orcid":"https://orcid.org/0000-0003-4616-8776","affiliations":[{"raw_affiliation_string":"EVERSANA, 113-3228 South Service Road, Burlington, Ontario L7N 3H8, Canada","institution_ids":["https://openalex.org/I4210153140"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022103583","display_name":"Elizabeth M. Salvo\u2010Halloran","orcid":"https://orcid.org/0000-0002-1850-9855","observed_orcids":["https://orcid.org/0000-0002-1850-9855"]},"institutions":[{"id":"https://openalex.org/I4210153140","display_name":"EVERSANA (Canada)","ror":"https://ror.org/04vgfdj66","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210153140"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Elizabeth M. Salvo-Halloran","raw_affiliation_strings":["EVERSANA, 113-3228 South Service Road, Burlington, Ontario L7N 3H8, Canada"],"raw_orcid":"https://orcid.org/0000-0002-1850-9855","affiliations":[{"raw_affiliation_string":"EVERSANA, 113-3228 South Service Road, Burlington, Ontario L7N 3H8, Canada","institution_ids":["https://openalex.org/I4210153140"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079247460","display_name":"John Sears","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112753","display_name":"CSL (United States)","ror":"https://ror.org/01jxhxv92","country_code":"US","type":"company","lineage":["https://openalex.org/I4210112753","https://openalex.org/I4210153402"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John Sears","raw_affiliation_strings":["CSL Behring, King of Prussia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CSL Behring, King of Prussia, PA, USA","institution_ids":["https://openalex.org/I4210112753"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102816083","display_name":"Yinglei Li","orcid":"https://orcid.org/0000-0003-3549-3805","observed_orcids":["https://orcid.org/0000-0003-3549-3805"]},"institutions":[{"id":"https://openalex.org/I4210112753","display_name":"CSL (United States)","ror":"https://ror.org/01jxhxv92","country_code":"US","type":"company","lineage":["https://openalex.org/I4210112753","https://openalex.org/I4210153402"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yinglei Li","raw_affiliation_strings":["CSL Behring, King of Prussia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CSL Behring, King of Prussia, PA, USA","institution_ids":["https://openalex.org/I4210112753"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047508914","display_name":"Maebh Kelly","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I111268130","display_name":"CSL (United Kingdom)","ror":"https://ror.org/05mrzft53","country_code":"GB","type":"company","lineage":["https://openalex.org/I111268130","https://openalex.org/I4210153402"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Maebh Kelly","raw_affiliation_strings":["CSL Behring Ltd, Haywards Heath, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CSL Behring Ltd, Haywards Heath, UK","institution_ids":["https://openalex.org/I111268130"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073575407","display_name":"Simona Gavata-Steiger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I62612085","display_name":"CSL (Switzerland)","ror":"https://ror.org/01400tq86","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210153402","https://openalex.org/I62612085"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Simona Gavata-Steiger","raw_affiliation_strings":["CSL Behring AG, Bern, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CSL Behring AG, Bern, Switzerland","institution_ids":["https://openalex.org/I62612085"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074782563","display_name":"Chiara Nenci","orcid":"https://orcid.org/0000-0003-2319-2909","observed_orcids":["https://orcid.org/0000-0003-2319-2909"]},"institutions":[{"id":"https://openalex.org/I62612085","display_name":"CSL (Switzerland)","ror":"https://ror.org/01400tq86","country_code":"CH","type":"company","lineage":["https://openalex.org/I4210153402","https://openalex.org/I62612085"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Chiara Nenci","raw_affiliation_strings":["CSL Behring AG, Bern, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CSL Behring AG, Bern, Switzerland","institution_ids":["https://openalex.org/I62612085"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062414386","display_name":"Iris C. Jacobs","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112753","display_name":"CSL (United States)","ror":"https://ror.org/01jxhxv92","country_code":"US","type":"company","lineage":["https://openalex.org/I4210112753","https://openalex.org/I4210153402"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Iris Jacobs","raw_affiliation_strings":["CSL Behring, King of Prussia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CSL Behring, King of Prussia, PA, USA","institution_ids":["https://openalex.org/I4210112753"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058969386","display_name":"Ingo Pragst","orcid":"https://orcid.org/0000-0002-1259-5422","observed_orcids":["https://orcid.org/0000-0002-1259-5422"]},"institutions":[{"id":"https://openalex.org/I4210105121","display_name":"Behringwerke (Germany)","ror":"https://ror.org/01647vc39","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210105121"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Ingo Pragst","raw_affiliation_strings":["CSL Behring GmbH, Marburg, Germany"],"raw_orcid":"https://orcid.org/0000-0002-1259-5422","affiliations":[{"raw_affiliation_string":"CSL Behring GmbH, Marburg, Germany","institution_ids":["https://openalex.org/I4210105121"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110356953","display_name":"Neelanjana Ray","orcid":"https://orcid.org/0000-0002-9397-6680","observed_orcids":["https://orcid.org/0000-0002-9397-6680"]},"institutions":[{"id":"https://openalex.org/I4210112753","display_name":"CSL (United States)","ror":"https://ror.org/01jxhxv92","country_code":"US","type":"company","lineage":["https://openalex.org/I4210112753","https://openalex.org/I4210153402"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Neelanjana Ray","raw_affiliation_strings":["CSL Behring, King of Prussia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"CSL Behring, King of Prussia, PA, USA","institution_ids":["https://openalex.org/I4210112753"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5038851166","display_name":"Imtiaz A. Samjoo","orcid":"https://orcid.org/0000-0003-1415-8055","observed_orcids":["https://orcid.org/0000-0003-1415-8055"]},"institutions":[{"id":"https://openalex.org/I4210153140","display_name":"EVERSANA (Canada)","ror":"https://ror.org/04vgfdj66","country_code":"CA","type":"company","lineage":["https://openalex.org/I4210153140"]}],"countries":["CA"],"is_corresponding":true,"raw_author_name":"Imtiaz A. Samjoo","raw_affiliation_strings":["EVERSANA, 113-3228 South Service Road, Burlington, Ontario L7N 3H8, Canada. Imtiaz.Samjoo@Eversana.com"],"raw_orcid":"https://orcid.org/0000-0003-1415-8055","affiliations":[{"raw_affiliation_string":"EVERSANA, 113-3228 South Service Road, Burlington, Ontario L7N 3H8, Canada. Imtiaz.Samjoo@Eversana.com","institution_ids":["https://openalex.org/I4210153140"]}]}],"institutions":[],"countries_distinct_count":5,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5038851166"],"corresponding_institution_ids":["https://openalex.org/I4210153140"],"apc_list":{"value":3490,"currency":"USD","value_usd":3490},"apc_paid":{"value":3490,"currency":"USD","value_usd":3490},"fwci":2.2128,"has_fulltext":true,"cited_by_count":15,"citation_normalized_percentile":{"value":0.90062521,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":100},"biblio":{"volume":"25","issue":"2","first_page":"161","last_page":"178"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11917","display_name":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11917","display_name":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11280","display_name":"Hemophilia Treatment and Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10498","display_name":"Migraine and Headache Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hereditary-angioedema","display_name":"hereditary angioedema","score":1.0},{"id":"https://openalex.org/keywords/long-term-prophylaxis","display_name":"long-term prophylaxis","score":0.9869999885559082},{"id":"https://openalex.org/keywords/garadacimab","display_name":"garadacimab","score":0.9940000176429749},{"id":"https://openalex.org/keywords/lanadelumab","display_name":"lanadelumab","score":1.0},{"id":"https://openalex.org/keywords/berotralstat","display_name":"berotralstat","score":0.9990000128746033},{"id":"https://openalex.org/keywords/treatment-efficacy","display_name":"treatment efficacy","score":0.5120000243186951},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7509999871253967},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.9779999852180481},{"id":"https://openalex.org/keywords/indirect-comparison","display_name":"indirect comparison","score":0.5270000100135803}],"concepts":[{"id":"https://openalex.org/C2777788586","wikidata":"https://www.wikidata.org/wiki/Q2096745","display_name":"Hereditary angioedema","level":2,"score":0.9819159507751465},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7563865780830383},{"id":"https://openalex.org/C3020646304","wikidata":"https://www.wikidata.org/wiki/Q1773974","display_name":"Prophylactic treatment","level":2,"score":0.6924118995666504},{"id":"https://openalex.org/C61797465","wikidata":"https://www.wikidata.org/wiki/Q1188986","display_name":"Term (time)","level":2,"score":0.567216157913208},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.523465096950531},{"id":"https://openalex.org/C2777995640","wikidata":"https://www.wikidata.org/wiki/Q1129007","display_name":"Angioedema","level":2,"score":0.5044406652450562},{"id":"https://openalex.org/C95190672","wikidata":"https://www.wikidata.org/wiki/Q815382","display_name":"Meta-analysis","level":2,"score":0.4906107485294342},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.31547850370407104},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.25275421142578125},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C62520636","wikidata":"https://www.wikidata.org/wiki/Q944","display_name":"Quantum mechanics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D050718","descriptor_name":"Complement C1 Inhibitor Protein","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D050718","descriptor_name":"Complement C1 Inhibitor Protein","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D050718","descriptor_name":"Complement C1 Inhibitor Protein","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D054179","descriptor_name":"Angioedemas, Hereditary","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D054179","descriptor_name":"Angioedemas, Hereditary","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1007/s40268-025-00511-y","doi":"https://doi.org/10.1007/s40268-025-00511-y","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40268-025-00511-y","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40268-025-00511-y.pdf","source":{"id":"https://openalex.org/S35266406","display_name":"Drugs in R&D","issn_l":"1174-5886","issn":["1174-5886","1179-6901"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","oarl","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs in R&D","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:10995630","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12185836","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":null,"raw_type":"Text"},{"id":"pmid:40434599","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/40434599","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs in R&D","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:12185836","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12185836/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs R D","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:c8e14ed863e944218d36fdfb8677a59a","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/c8e14ed863e944218d36fdfb8677a59a","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Drugs in R&D, Vol 25, Iss 2, Pp 161-178 (2025)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1007/s40268-025-00511-y","doi":"https://doi.org/10.1007/s40268-025-00511-y","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s40268-025-00511-y","pdf_url":"https://link.springer.com/content/pdf/10.1007/s40268-025-00511-y.pdf","source":{"id":"https://openalex.org/S35266406","display_name":"Drugs in R&D","issn_l":"1174-5886","issn":["1174-5886","1179-6901"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","oarl","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drugs in R&D","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/systematic-review","display_name":"Systematic Review"},{"id":"https://openalex.org/study-designs/meta-analysis","display_name":"Meta-Analysis"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320310420","display_name":"CSL Behring","ror":"https://ror.org/01jxhxv92"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4410829664.pdf","grobid_xml":"https://content.openalex.org/works/W4410829664.grobid-xml"},"referenced_works_count":31,"referenced_works":["https://openalex.org/W1617328014","https://openalex.org/W1973269051","https://openalex.org/W2004474087","https://openalex.org/W2010699829","https://openalex.org/W2125776201","https://openalex.org/W2127622911","https://openalex.org/W2129821518","https://openalex.org/W2150529573","https://openalex.org/W2161374186","https://openalex.org/W2169205464","https://openalex.org/W2599824295","https://openalex.org/W2793490143","https://openalex.org/W2886386212","https://openalex.org/W2902818271","https://openalex.org/W2920804790","https://openalex.org/W2981805492","https://openalex.org/W3024497439","https://openalex.org/W3026657539","https://openalex.org/W3083179120","https://openalex.org/W3087080946","https://openalex.org/W3110081665","https://openalex.org/W3118615836","https://openalex.org/W3126226315","https://openalex.org/W3131722049","https://openalex.org/W3133592831","https://openalex.org/W4214686760","https://openalex.org/W4322604179","https://openalex.org/W4377564030","https://openalex.org/W4392351146","https://openalex.org/W4396626940","https://openalex.org/W4405320044"],"related_works":["https://openalex.org/W4417017105","https://openalex.org/W4386296008","https://openalex.org/W4412155371","https://openalex.org/W4377564030","https://openalex.org/W4391534993","https://openalex.org/W4411200740","https://openalex.org/W4393299520","https://openalex.org/W4406687052","https://openalex.org/W4402587594","https://openalex.org/W7202000544"],"abstract_inverted_index":{"BACKGROUND":[0],"AND":[1],"OBJECTIVES:":[2],"Several":[3],"treatments":[4,43,68,90],"for":[5,69,117,210],"long-term":[6],"prophylaxis":[7],"(LTP)":[8],"of":[9,31,50,64,66,123,130,140,175,183,186,195,225],"hereditary":[10],"angioedema":[11],"(HAE)":[12],"are":[13,38],"in":[14,44,91,172,222,240,244],"clinical":[15],"use,":[16],"such":[17],"as":[18,248,256],"garadacimab,":[19],"lanadelumab,":[20],"subcutaneous":[21,157,270],"C1":[22],"esterase":[23],"inhibitor":[24],"(C1INH),":[25],"and":[26,60,112,121,137,163,201],"berotralstat.":[27,202,251],"In":[28],"the":[29,56,173,180,193,223,257],"absence":[30],"head-to-head":[32],"comparative":[33,57],"evidence,":[34],"indirect":[35],"comparison":[36],"methods":[37],"needed":[39],"to":[40,54,82,170,198,232,250],"compare":[41],"LTP":[42,67,89],"patients":[45,70,92,176],"with":[46,71,98,143,177,214,266],"HAE.":[47,178],"The":[48,128],"objective":[49],"this":[51],"analysis":[52],"was":[53,80,208],"estimate":[55],"efficacy,":[58,119,135],"safety,":[59,120],"impact":[61],"on":[62],"quality":[63,122],"life":[65,124],"HAE":[72,99,187,211,229],"through":[73],"NMAs.":[74],"METHODS:":[75],"A":[76,103,203],"systematic":[77],"literature":[78],"review":[79],"conducted":[81,116],"identify":[83],"randomized":[84],"controlled":[85],"trials":[86],"(RCTs)":[87],"investigating":[88],"(at":[93],"least":[94],"12":[95],"years":[96],"old)":[97],"(PROSPERO":[100],"protocol":[101],"#CRD42022359207).":[102],"network":[104],"meta-analysis":[105],"(NMA)":[106],"feasibility":[107],"assessment":[108],"evaluated":[109],"trial":[110],"suitability":[111],"Bayesian":[113],"NMAs":[114,132],"were":[115],"evaluable":[118],"(QoL)":[125],"outcomes.":[126,276],"RESULTS:":[127],"results":[129],"these":[131],"show":[133],"improved":[134],"QoL,":[136],"reduced":[138,192],"rate":[139,194,224],"adverse":[141],"events":[142],"garadacimab":[144,189,254],"(200":[145],"mg":[146,151,166],"once":[147,167],"monthly),":[148],"lanadelumab":[149,199,233,267],"(300":[150],"every":[152],"two":[153],"or":[154,269],"four":[155],"weeks),":[156],"C1INH":[158,271],"(60":[159],"IU/kg":[160],"twice":[161],"weekly),":[162],"berotralstat":[164],"(150":[165],"daily)":[168],"compared":[169,197,231,249],"placebo":[171],"treatment":[174,261],"For":[179],"primary":[181],"outcome":[182],"time-normalized":[184],"number":[185],"attacks,":[188],"statistically":[190,205,219],"significantly":[191],"attacks":[196,212,230],"Q4W":[200],"similar":[204],"significant":[206,220],"reduction":[207,221],"shown":[209],"treated":[213],"on-demand":[215],"treatment.":[216],"Garadacimab":[217,235],"showed":[218,237],"moderate":[226],"and/or":[227],"severe":[228],"Q2W.":[234],"also":[236],"statistical":[238],"improvements":[239],"change":[241],"from":[242],"baseline":[243],"AE-QoL":[245],"total":[246],"score":[247],"CONCLUSIONS:":[252],"Overall,":[253],"ranked":[255],"most":[258,275],"probable":[259],"effective":[260],"among":[262],"all":[263],"comparators":[264],"assessed,":[265],"Q2W":[268],"ranking":[272],"second,":[273],"across":[274]},"counts_by_year":[{"year":2026,"cited_by_count":13},{"year":2025,"cited_by_count":2}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2025-10-10T00:00:00"}